Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NM32-2668 in advanced solid tumors
NCT06299163Phase 1Terminated
- Sponsor
- Numab Therapeutics AG
- Start
- May 2024
- Primary completion
- Apr 2025
- Modality
- Trispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NM32-2668 in ovarian carcinoma, fallopian tube carcinoma (PFTC), primary peritoneal carcinoma (PPC) and 10 more, sponsored by Numab Therapeutics AG. Primary endpoints: Incidence of Dose Limiting Toxicities at 28 days, Number of participants with treatment-emergent adverse events and serious adverse events at 50 days and 2 more. Started May 2024; status: terminated.
02
Drugs
NM32-2668
03
Conditions
ovarian carcinomafallopian tube carcinoma (PFTC)primary peritoneal carcinoma (PPC)endometrial cancer (EC)lung adenocarcinoma
Beyond the preview
Go deeper on NCT06299163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06299163.